Trials / No Longer Available
No Longer AvailableNCT00878943
Open Label Access Study Of Sildenafil In Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study
A Local, Multi-centre, Open Label Access Study, To Provide Sildenafil Therapy To Eligible Adult Patients With Pulmonary Arterial Hypertension Completing A1481244 Study In India Or Ongoing In A1481269 Study Who Continue To Receive Benefit From Sildenafil Therapy.
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In an earlier study, sildenafil citrate administered to patients of PAH led to improvement in pulmonary arterial pressure, cardiac output, quality of life, and other parameters as compared to placebo. This protocol provides mechanism for patients who have clinical deterioration on other PAH approved therapies to have access to sildenafil prior to marketing authorization in India.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sildenafil citrate | 20 mg tablet to be taken thrice daily for 1 year |
Timeline
- First posted
- 2009-04-09
- Last updated
- 2021-02-01
Locations
5 sites across 1 country: India
Source: ClinicalTrials.gov record NCT00878943. Inclusion in this directory is not an endorsement.